

Supplementary Table 1.

Patient	Age/ Sex	Clinicopathologic diagnosis	AJCC Stage	Prior treatment	Pleural Infusion Treatment (IP)	Changes of PE			Evaluation	Survival (months)
						UE	Color	Turbidity		
1	66/F	Lung adenocarcinoma	IV	DP 4 cycles PP 3 cycles	5U cisplatin-MP × 4 times	B: left 6.4cm A: left 2.9cm	B: Red A: Yellow	B: Turbid A: Bright	PR	10
2	58/M	Lung adenocarcinoma	IV	IP cisplatin 1 time	5U cisplatin-MP × 4 times	B: left 9.7cm A: left 3.7cm	B: Red A: Yellow	B: Turbid A: Bright	PR	6
3	56/M	Lung adenocarcinoma	IV	PP 3 cycles PC 2 cycles	5U cisplatin-MP × 4 times	B: left 5.5cm A: left —	B: Red A: Yellow	B: Turbid A: Bright	CR	3
4	64/F	Lung adenocarcinoma	IV	PP 3 cycles	cisplatin 2 time (60mg each)	B: left 8.8cm A: left 7.5cm	B: Red A: Red	B: Turbid A: Turbid	NC	5
5	75/M	Lung adenocarcinoma	IV	PP 1 cycles	cisplatin 2 times (60mg each)	B: left 8.9cm A: left 11.8cm	B: Yellow A: Red	B: Turbid A: Turbid	NC	3
6	58/F	Lung adenocarcinoma	IV	PP 2 cycles	cisplatin 2 times (60mg each)	B: left 9.3cm A: left 7.2cm	B: Red A: Red	B: Turbid A: Turbid	SD	2

F: female; M: male; DP: docetaxel+cisplatin; PP: pemetrexed+cisplatin; PC: taxol+carboplatin; IP: intrapleural perfusion;

1U (1Unit)= $1 \times 10^7$  cisplatin-MP=10 $\mu$ g; PE: Pleural effusion; UE: ultrasonic examination; B: before; A: after; left: left pleural cavity;

PR: partial response; CR: complete remission; NC: no change; SD: stable disease.

**Supplementary information, Table S1. Outcomes of clinical treatment (Related to Figure 1).**